Atrovent Nasal Spray
"In the largest, most comprehensive, nationwide study to examine the prevalence of allergies from early childhood to old age, scientists from the National Institutes of Health report that allergy prevalence is the same across different regions "...
Atrovent Nasal Spray
ATROVENT Nasal Spray (ipratropium bromide nasal spray) 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older.
ATROVENT Nasal Spray (ipratropium bromide nasal spray) 0.03% does not relieve nasal congestion, sneezing, or postnasal drip associated with allergic or nonallergic perennial rhinitis.
DOSAGE AND ADMINISTRATION
The recommended dose of ATROVENT Nasal Spray (ipratropium bromide nasal spray) 0.03% is two sprays (42 mcg) per nostril two or three times daily (total dose 168 to 252 mcg/day) for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. Optimum dosage varies with the response of the individual patient.
Initial pump priming requires seven sprays of the pump. If used regularly as recommended, no further priming is required. If not used for more than 24 hours, the pump will require two sprays, or if not used for more than seven days, the pump will require seven sprays to reprime. Avoid spraying into eyes.
Atrovent® (ipratropium bromide) Nasal Spray 0.03% is supplied in a white high density polyethylene (HDPE) bottle fitted with a metered nasal spray pump, a green safety clip to prevent accidental discharge of the spray, and a clear plastic dust cap. It contains 31.1g of product formulation, 345 sprays, each delivering 21 mcg of ipratropium bromide per spray (70 μL), or 28 days of therapy at the maximum recommended dose (two sprays per nostril three times a day) (NDC 0597-0081-30).
Store tightly closed at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. Avoid freezing. Keep out of reach of children. Do not spray in the eyes.
Address medical inquiries to: http://us.boehringer-ingelheim.com, (800) 542-6257 or (800)459-9906 TTY.
Patients should be reminded to read and follow the accompanying “Patient's Instructions for Use”, which should be dispensed with the product.
Distributed by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA. Rev: May 2007. FDA rev date: 11/30/2007This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 12/5/2008
Additional Atrovent Nasal Spray Information
- Atrovent Nasal Spray Drug Interactions Center: ipratropium bromide nasl
- Atrovent Nasal Spray Side Effects Center
- Atrovent Nasal Spray in detail including Side Effects and Drug Images
- Atrovent Nasal Spray Overview including Precautions
- Atrovent Nasal Spray FDA Approved Prescribing Information including Dosage
Atrovent Nasal Spray - User Reviews
Atrovent Nasal Spray User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Allergies & Asthma
Improve treatments & prevent attacks.